Akèy › Enfeksyon Viris Epstein-Barr
Etid klinik pou Enfeksyon Viris Epstein-Barr ap rekrite nan Etazini
16 etid pou Enfeksyon Viris Epstein-Barr ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT03258567Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 29 · Tout sèks · Mizajou Sep 8, 2026 · NCT06908096Donor-Derived Viral Specific T-cells (VSTs)
Ap rekriteFaz 1/2
4 Weeks · Tout sèks · Mizajou Sep 4, 2026 · NCT02048332Third Party Viral Specific T-cells (VSTs)
Ap rekriteFaz 2
2 Days · Tout sèks · Mizajou Sep 4, 2026 · NCT02532452A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT06789159A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Ap rekriteFaz 3
Tout laj · Tout sèks · Mizajou Sep 2, 2026 · NCT03394365Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Aug 25, 2026 · NCT05389423A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 11, 2026 · NCT05592626R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Ap rekriteFaz 1
3 Months – 26 Years · Tout sèks · Mizajou Jul 30, 2026 · NCT06926894Genetic Studies of Chronic Active Epstein-Barr Disease
Ap rekriteEtid obsèvasyon
Laj 1 a 120 · Tout sèks · Mizajou Jul 28, 2026 · NCT00032513EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Jun 25, 2026 · NCT04664179Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT06682442TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Ap rekriteFaz 1
Tout laj · Tout sèks · Mizajou Jun 11, 2026 · NCT04013802R-MVST Cells for Treatment of Viral Infections
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 10, 2026 · NCT05183490Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Ap rekriteFaz 1/2
1 Month – 65 Years · Tout sèks · Mizajou Aug 14, 2025 · NCT06909110EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
Ap rekriteFaz 2
1 Month – 79 Years · Tout sèks · Mizajou Aug 8, 2025 · NCT03266653Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.